The treatment of cervical dystonia with botulinum toxins

被引:27
作者
Comella, C. L. [1 ]
机构
[1] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA
关键词
cervical dystonia; spasmodic torticollis; botulinum toxins; controlled trials; review;
D O I
10.1007/s00702-007-0831-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Botulinum neurotoxin (BoNT) treatment has been used extensively for the treatment of cervical dystonia. There are three established brands and two serotypes of BoNT commercially available in most of the world, and several additional brands are available in selected geographic regions. In most controlled studies, there is significant improvement following treatment for head posture, pain and disability. The common side effects of treatment include dysphagia, dry mouth, and neck weakness. Each brand and serotype is pharmacologically distinct. The dosing of each type differs, and no simple dose equivalency has been established. With repeated treatment, the development of immunoresistance is observed in a percentage of patients. However, it is likely that each brand and serotype may differ in immunogenic potential and occurrence of secondary unresponsiveness, an issue that is currently under active investigation.
引用
收藏
页码:579 / 583
页数:5
相关论文
共 30 条
  • [1] A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
    Benecke, R
    Jost, WH
    Kanovsky, P
    Ruzicka, E
    Comes, G
    Grafe, S
    [J]. NEUROLOGY, 2005, 64 (11) : 1949 - 1951
  • [2] Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia
    Berman, B
    Seeberger, L
    Kumar, R
    [J]. MOVEMENT DISORDERS, 2005, 20 (02) : 233 - 237
  • [3] Botulinum toxin versus trihexyphenidyl in cervical dystoni - A prospective, randomized, double-blind controlled trial
    Brans, JWM
    Lindeboom, R
    Snoek, JW
    Zwarts, MJ
    vanWeerden, TW
    Brunt, ERP
    vanHilten, JJ
    vanderKamp, W
    Prins, MH
    Speelman, JD
    [J]. NEUROLOGY, 1996, 46 (04) : 1066 - 1072
  • [4] Brashear A, 2000, MOVEMENT DISORD, V15, P150, DOI 10.1002/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO
  • [5] 2-X
  • [6] Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
    Brashear, A
    Lew, MF
    Dykstra, DD
    Comella, CL
    Factor, SA
    Rodnitzky, RL
    Trosch, R
    Singer, C
    Brin, MF
    Murray, JJ
    Wallace, JD
    Willmer-Hulme, A
    Koller, M
    [J]. NEUROLOGY, 1999, 53 (07) : 1439 - 1446
  • [7] Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
    Brin, MF
    Lew, MF
    Adler, CH
    Comella, CL
    Factor, SA
    Jankovic, J
    O'Brien, C
    Murray, JJ
    Wallace, JD
    Willmer-Hulme, A
    Koller, M
    [J]. NEUROLOGY, 1999, 53 (07) : 1431 - 1438
  • [8] Impact of cervical dystonia on quality of life
    Camfield, L
    Ben-Shlomo, Y
    Warner, TT
    [J]. MOVEMENT DISORDERS, 2002, 17 (04) : 838 - 841
  • [9] IDIOPATHIC CERVICAL DYSTONIA - CLINICAL CHARACTERISTICS
    CHAN, J
    BRIN, MF
    FAHN, S
    [J]. MOVEMENT DISORDERS, 1991, 6 (02) : 119 - 126
  • [10] Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia
    Comella, CL
    Jankovic, J
    Shannon, KM
    Tsui, J
    Swenson, M
    Leurgans, S
    Fan, W
    [J]. NEUROLOGY, 2005, 65 (09) : 1423 - 1429